Plasma CD16 <sup>+</sup> Extracellular Vesicles Associate with Carotid Artery Intima-Media Thickness in HIV <sup>+</sup> Adults on Combination Antiretroviral Therapy-Reference-Cited by-同舟云学术

Plasma CD16 ⁺ Extracellular Vesicles Associate with Carotid Artery Intima-Media Thickness in HIV ⁺ Adults on Combination Antiretroviral Therapy

Published:2022-06-28 Issue:3 Volume:13 Page:
ISSN:2150-7511
Container-title:mBio
language:en
Short-container-title:mBio

Author:

Marques de Menezes Erika G.¹²^ORCID,Deng Xutao¹²,Liu Jocelyn³,Bowler Scott A.³,Shikuma Cecilia M.⁴⁵,Stone Mars¹²,Hunt Peter W.⁶,Ndhlovu Lishomwa C.³⁴,Norris Philip J.¹²⁶

Affiliation:

1. Vitalant Research Institute, San Francisco, California, USA

2. Department of Laboratory Medicine, University of California, San Francisco, California, USA

3. Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, New York, USA

4. Department of Tropical Medicine, University of Hawaii, Honolulu, Hawaii, USA

5. Department of Medicine, Hawaii Center for AIDS, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, USA

6. Department of Medicine, UCSF, San Francisco, California, USA

Abstract

HIV-infected individuals have a 2-fold-increased risk of cardiovascular disease compared with the general population, yet the mechanisms underlying this comorbidity are unclear. Extracellular vesicles have emerged as important mediators in cell-cell communication and, given what we know of their biology, may drive inflammation contributing to cardiovascular disease in this vulnerable population.

Funder

HHS | National Institutes of Health

Publisher

American Society for Microbiology

Subject

Virology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/mbio.03005-21

Reference56 articles.

1. Global Burden of Atherosclerotic Cardiovascular Disease in People Living With HIV

2. Longitudinal management and outcomes of acute coronary syndrome in persons living with HIV infection

3. Association Between HIV Infection and the Risk of Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction in the Antiretroviral Therapy Era